<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150566</url>
  </required_header>
  <id_info>
    <org_study_id>SPD405-312</org_study_id>
    <nct_id>NCT00150566</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood</brief_title>
  <official_title>A Phase IIIb, Multi-center, Two-Cohort, Randomized Study, With an Open-Label Run-In and a Long-Term Extensions Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test how well higher doses of lanthanum carbonate reduce the&#xD;
      pre-dialysis level of serum phosphorus in subjects undergoing dialysis due to end stage renal&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2004</start_date>
  <completion_date type="Actual">October 8, 2005</completion_date>
  <primary_completion_date type="Actual">October 8, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dialysis serum phosphate levels after 4 and 8 weeks of treatment</measure>
    <time_frame>4 &amp; 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject/physician satisfaction and preference questionnaires</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <enrollment>460</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with ESRD who currently require treatment for hyperphosphatemia&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum beta HCG pregnancy test and&#xD;
             must agree to abstain from sexual activity or to use acceptable contraceptives from&#xD;
             the time of informed consent throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with compounds containing calcium, aluminum or magnesium for use as a&#xD;
             phosphate binder&#xD;
&#xD;
          -  Hypocalcaemia&#xD;
&#xD;
          -  Treatment-naive to any phosphate binder with a serum phosphorus &lt; 5.5 mg/dL&#xD;
&#xD;
          -  Any significant gastrointestinal surgery or gastrointestinal disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall Information</description>
  </link>
  <results_reference>
    <citation>Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M; Fosrenol Overview Research Evaluation Study for Early Experience Study Group. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep;3(5):1437-45. doi: 10.2215/CJN.04741107. Epub 2008 Jun 25.</citation>
    <PMID>18579668</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

